Reddy Vikram B, Longo Walter E
Dr. Reddy is an Assistant Professor of Colon and Rectal Surgery in the Department of Surgery at Yale University School of Medicine in New Haven, Connecticut, where Dr. Longo is a Professor of Surgery (Gastrointestinal); a Professor of Obstetrics, Gynecology, and Reproductive Sciences; and Section Chief and Director of Colon and Rectal Surgery.
Gastroenterol Hepatol (N Y). 2013 Jan;9(1):21-7.
Diverticulitis is a debilitating complication of diverticular disease that affects approximately 2.5 million individuals in the United States. Compared to many other gastrointestinal conditions, diverticular disease is poorly understood in terms of its burden on patients and healthcare systems. This review examines the existing literature and discusses the current knowledge of the burden of diverticular disease. Literature confirmed that bothersome symptoms (such as abdominal pain and bloating) and potentially serious, disease-related complications (such as diverticulitis and diverticular bleeding) place a significant burden on patients. Broad-spectrum antibiotic therapy and surgery are the generally accepted mainstays of treatment for acute complications of diverticular disease. Despite these options, patients frequently experience substantially reduced quality of life (particularly in terms of social and emotional functioning) and increased mortality (predominantly due to disease-related complications) compared to healthy controls. Furthermore, diverticular disease accounted for 254,179 inpatient discharges and 1,493,865 outpatient clinic visits in the United States in 2002, at an estimated cost per hospitalization of $9,742-$11,729. Enhancing the quality of life of patients with diverticular disease and reducing disease exacerbations and complications will substantially benefit patients and healthcare systems. However, long-established treatment algorithms fall short of these therapeutic goals. Research into new treatment options for patients with diverticular disease should therefore be pursued.
憩室炎是憩室病的一种使人虚弱的并发症,在美国约有250万人受其影响。与许多其他胃肠道疾病相比,憩室病对患者和医疗系统造成的负担尚未得到充分了解。本综述审视了现有文献,并讨论了目前对憩室病负担的认识。文献证实,令人烦恼的症状(如腹痛和腹胀)以及潜在的严重疾病相关并发症(如憩室炎和憩室出血)给患者带来了巨大负担。广谱抗生素治疗和手术是憩室病急性并发症普遍公认的主要治疗方法。尽管有这些治疗选择,但与健康对照组相比,患者的生活质量常常大幅下降(尤其是在社交和情感功能方面),死亡率也有所上升(主要是由于疾病相关并发症)。此外,2002年在美国,憩室病导致了254,179例住院出院和1,493,865次门诊就诊,估计每次住院费用为9,742美元至11,729美元。提高憩室病患者的生活质量,减少疾病加重和并发症,将使患者和医疗系统受益匪浅。然而,长期确立的治疗方案未能实现这些治疗目标。因此,应该对憩室病患者的新治疗选择进行研究。
Gastroenterol Hepatol (N Y). 2013-1
Am J Gastroenterol. 2012-7-10
Inflamm Intest Dis. 2018-12
Korean J Gastroenterol. 2022-6-25
Drugs Aging. 2004
Br J Nurs. 2023-2-23
Rozhl Chir. 2009-10
J Mech Behav Biomed Mater. 2024-12
Ann Surg Open. 2022-9-27
Aliment Pharmacol Ther. 2009-7-20
Natl Vital Stat Rep. 2007-8-21
J Gastroenterol Hepatol. 2007-9
Hepatogastroenterology. 2007
Dig Dis. 2007